# Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

> **NCT05636904** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dermaliq Therapeutics, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Androgenetic Alopecia

## Interventions

- **DRUG:** prostaglandin F2a analogue in vehicle solution high dose
- **DRUG:** prostaglandin F2a analogue in vehicle solution low dose
- **DRUG:** active ingredient-free vehicle solution to DLQ01
- **DRUG:** Minoxidil 5% Topical Solution

## Key facts

- **NCT ID:** NCT05636904
- **Lead sponsor:** Dermaliq Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-05
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-03-28
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636904, "Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05636904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*